The Omics of Triple-Negative Breast Cancers

Abstract excerpt

BACKGROUND: Triple-negative breast cancers (TNBC) do not represent a single disease subgroup and are often aggressive breast cancers with poor prognoses. Unlike estrogen/progesterone receptor and HER2 (human epidermal growth factor receptor 2) breast cancers, which are responsive to targeted treatments, there is no effective targeted therapy for TNBC, although approximately 50% of patients respond to conventional...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Cancer Treatment Studies
• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations